<b>Results</b>: Chronic SGLT2 inhibitor therapy was associated with reduced first rehospitalization (HR 0.64; 95% CI 0.48-0.85; <i>p</i> = 0.002) and a lower cumulative rehospitalization burden (IRR 0.61; 95% CI 0.46-0.82; <i>p</i> = 0.001), primarily driven by heart failure-related and metabolic phenotypes. The gene discussed is SLC5A2; the disease is heart failure.